Antibiotic Trials for Coronary Heart Disease
AUTOR(ES)
Anderson, Jeffrey L.
RESUMO
The possibility has been raised in recent years that infection might contribute as an inflammatory stimulus to chronic “noninfectious” degenerative diseases. Within the past decade, serious attention has been given to the possibility of bacterial vectors as causal factors of atherosclerosis. To date, the greatest amount of information has related to the intracellular organism Chlamydia pneumoniae. This interest has been stimulated by the frequent finding of bacterial antigens and, occasionally, recoverable organisms, within human atherosclerotic plaque. Indirect evidence for and against the benefit of anti-Chlamydia antibiotic agents comes from epidemiologic studies.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=387430Documentos Relacionados
- Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials
- Randomised trials of secondary prevention programmes in coronary heart disease: systematic review
- Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
- Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
- Screening for risk of coronary heart disease